The differential contribution of the classical and trans-signaling IL-6 pathways in cell-mediated inflammatory processes was recently demonstrated in the experiment of pharmaceutically targeting each of them using two murine models of human arthritis. This evidence concerns the gene IL6 and arthritic joint disease.